<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10555759</article-id><article-id pub-id-type="pmc">2374283</article-id><article-id pub-id-type="pii">6690777</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690777</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Evolution of BCL-2/IgH hybrid gene RNA expression during treatment of T(14;18)-bearing follicular lymphomas</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Soubeyran</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hostein</surname><given-names>I</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Debled</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Eghbali</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib><contrib contrib-type="author"><name><surname>Soubeyran</surname><given-names>I</given-names></name><xref ref-type="aff" rid="aff1">3</xref></contrib><contrib contrib-type="author"><name><surname>Bonichon</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff1">4</xref></contrib><contrib contrib-type="author"><name><surname>Astier-Gin</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>H&#x00153;rni</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff1">2</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Departments of Molecular Oncology, <label>2</label>Haematology, <label>3</label>Pathology and<label>4</label>Statistics, Institut Bergoni&#x000e9;, Regional Cancer Center, 180 rue de Saint-Gen&#x000e8;s, Bordeaux Cedex, 33076, France</aff><aff id="aff5"><label>5</label>Unit&#x000e9; INSERM 328, Bordeaux Cedex 33076, France</aff><pub-date pub-type="ppub"><month>11</month><year>1999</year></pub-date><volume>81</volume><issue>5</issue><fpage>860</fpage><lpage>869</lpage><history><date date-type="received"><day>07</day><month>10</month><year>1998</year></date><date date-type="rev-recd"><day>12</day><month>04</month><year>1999</year></date><date date-type="accepted"><day>22</day><month>04</month><year>1999</year></date></history><copyright-statement>Copyright 1999, Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Bcl-2, the gene over-expressed in follicular lymphomas (FL), is able to block chemotherapy-induced apoptosis. Consequently, we wondered whether bcl-2/IgH expression variations during treatment of FL could predict the outcome of patients with t(14;18)-bearing FL. For this purpose, we used a reverse transcription polymerase chain reaction (RT-PCR) assay to analyse 180 serial peripheral blood samples (PBS) during 34 treatment phases in 25 patients with t(14;18)-bearing FL. In all patients but two, bcl-2/IgH gene expression was demonstrated in pre-treatment samples. During 16 out of the 34 treatment phases (47&#x00025;), bcl-2/IgH expression became negative: all but one were responders to chemotherapy. This conversion was transient in six cases. In 18 treatment phases, bcl2/IgH expression remained detectable: eight were clinically considered as treatment failures, while eight others achieved PR and two achieved CR. We observed a significant correlation between treatment response and RNA PCR results (<italic>P</italic> = 0.002). Three-year overall survival of patients with stable bcl2/IgH-negative conversion was 100&#x00025; compared to 54&#x00025; for the remaining patients (<italic>P</italic> = 0.069); 3-year freedom from progression was respectively 87.5&#x00025; and 13&#x00025; (<italic>P</italic> = 0.005). These results indicate a correlation between bcl-2/IgH expression variations and both clinical response and outcome. Whether this might predict disease outcome early remains to be confirmed. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>non-Hodgkin&#x02019;s lymphoma</kwd><kwd>residual disease</kwd><kwd>t(14;18)</kwd><kwd>bcl-2</kwd><kwd>chemotherapy</kwd></kwd-group></article-meta></front></article>


